Form 4: Iovance Biotherapeutics Executive Vogt Reports Stock Transactions
SEC Form 4 Filing
Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On April 15, 2024, Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, had 20,834 restricted stock units (RSUs) vest.
- The company withheld 8,851 shares at a price of $11.89 to cover mandatory tax obligations.
- Following these transactions, Vogt directly owns 141,334 shares of common stock and 62,504 restricted stock units.
- These remaining RSUs will vest in equal quarterly installments.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions, with no inherent positive or negative implications for the company's performance.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common in the biopharmaceutical industry.
Stakeholder Impact
- The transactions have a minor impact on the total outstanding shares of Iovance Biotherapeutics.
Key Dates
| Date | Description |
|---|---|
| 01/14/2022 | Date of grant for the remaining RSUs held by the Reporting Person. |
| 04/15/2024 | Date of transaction: vesting of restricted stock units and tax withholding. |
| 04/17/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.